3SBio Inc. Announces First Quarter 20...( - Q1 2008 net revenues grew 56.8% ...)

- Q1 2008 net revenues grew 56.8%, as compared to Q1 2007, to RMB55.5

million (US$7.9 million) - Q1 2008 operating income grew 22.4%, as compared to Q1 2007, to RMB14.2

million (US$2.0 million)

- Q1 2008 net income grew 22.3%, as compared to Q1 2007, to RMB 19.8

million (US$2.8 million)

SHENYANG, China, May 14 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "the Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced its unaudited financial results for the first quarter ended March 31, 2008.

First Quarter 2008 Financial Highlights:

-- Total net revenues increased 56.8% over the first quarter 2007 to

RMB55.5 million (US$7.9 million).

-- Net revenue from our flagship injectable recombinant human

erythropoietin ("EPO") products, marketed under our EPIAO brand,

increased 41.2% over the first quarter 2007 to RMB35.5 million (US$5.1

million).

-- Net revenue from our protein-based therapeutic recombinant human

thrombopoietin ("TPO") products, marketed under our TPIAO brand,

increased 103.8% over the first quarter 2007 to RMB15.4 million (US$2.2

million).

-- Operating income increased 22.4% over the first quarter 2007 to

RMB14.2 million (US$2.0 million).

-- Net income increased 22.3% over the first quarter 2007 to RMB19.8

million (US$2.8 million).

-- Net income per American Depositary Share ("ADS") for the first

quarter 2008 was RMB0.91 (US$0.13). Each ADS represents seven ordinary